BRAF and colorectal carcinoma: In a set of patients with metastatic BRAF-mutant CRC treated with targeted therapy (i.e., dabrafenib, trametinib, and panitumumab), those with the BRAFV600E-mutant (BM) 2 subtype signature (BM2) (characterized by a low EMT and high oxidative phosphorylation [OXPHOS] and G2M cell cycle signatures) had the poorest prognosis (67, 68).